Results 161 to 170 of about 3,871 (190)
Some of the next articles are maybe not open access.
Thrombotic complications in patients with PMM2-CDG
Molecular Genetics and Metabolism, 2013Many proteins regulating coagulation, including factor IX, factor XI, Antithrombin-III, Protein C and Protein S are deficient or decreased in activity in congenital disorders of glycosylation (CDG). Because of the imbalance of coagulation and anticoagulation factors, some patients develop acute vascular events, such as thrombosis.
Linssen, M. +8 more
openaire +3 more sources
Assessing the effects of PMM2 variants on protein stability
Molecular Genetics and Metabolism, 2021Phosphomannomutase 2 deficiency, PMM2-CDG, is the most frequent disorder of protein N-glycosylation. It is an autosomal recessive disease with a broad clinical and biochemical phenotype. Trying to predict the impact of novel variants is often a challenge due to the high number of variants and the difficulty to establish solid genotype-phenotype ...
D, Quelhas +9 more
openaire +2 more sources
In the absence of prospective data on neurological symptoms, disease outcome, or guidelines for system specific management in phosphomannomutase 2-congenital disorders of glycosylation (PMM2-CDG), we aimed to collect and review natural history data.Fifty-one molecularly confirmed individuals with PMM2-CDG enrolled in the Frontiers of Congenital ...
Karthik Muthusamy
exaly +4 more sources
PMM2 intronic branch-site mutations in CDG-Ia
Molecular Genetics and Metabolism, 2006Congenital Disorders of Glycosylation (CDG, OMIM#212065)-Ia is an autosomal recessive disorder, characterized by central nervous system dysfunction and multiorgan failure associated with mutations in the PMM2 gene. We report two patients who are compound heterozygotes with respect to two new intronic mutations that affect a highly conserved adenosine ...
Sandrine, Vuillaumier-Barrot +7 more
openaire +2 more sources
Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2‐CDG)
Journal of Inherited Metabolic Disease, 2011AbstractDeficiency of phosphomannomutase (PMM2, MIM#601785) is the most common congenital disorder of glycosylation. Herein we report the genetic analysis of 22 Spanish PMM2 deficient patients and the functional analysis of 14 nucleotide changes in a prokaryotic expression system in order to elucidate their molecular pathogenesis.
Ana Isabel, Vega +8 more
openaire +2 more sources
Sensitivity of transferrin isoform analysis for PMM2-CDG
Molecular Genetics and MetabolismTransferrin isoform analysis is an established laboratory test for congenital disorders of glycosylation (CDG). Despite its long history of clinical use, little has been published about its empirical sensitivity for specific conditions. We conducted a retrospective analysis of ten years of testing data and report our experience with transferrin testing
Patrica L, Hall +12 more
openaire +2 more sources
Sugar-bisphosphates to cure PMM2-CDG?
2021INTRODUCTION PMM2-CDG is the most common congenital disorder of glycosylation (CDGs). It is caused by mutations in the gene PMM2, encoding the enzyme phosphomannomutase-2 (PMM2). A defective PMM2 leads to GDP- mannose deficiency and hypoglycosylation of numerous glycoproteins. At the present, PMM2-CDG has no cure. The use of pharmacological chaperones (
M. Allocca +3 more
openaire +1 more source
PMM2-CDG: Phenotype and genotype in four affected family members
Gene, 2013Congenital disorders of glycosylation (CDG) are genetic defects in protein and lipid glycosylation. PMM2-CDG is the most prevalent protein N-glycosylation disorder with more than 700 reported patients. Here we report on a large Italian family with four affected members and three mutations.
Bortot, Barbara +6 more
openaire +3 more sources
International Journal of Biological Macromolecules
PMM2-congenital disorder of glycosylation (PMM2-CDG) is caused by genetic defects in PMM2, the gene encoding phosphomannomutase 2. Effective therapies for this disorder remain elusive. Recent studies emphasize cysteine's vulnerability to oxidative modifications that can instigate disease by facilitating inter-protein disulfide bonding, reducing protein
Jingmiao, Sun +8 more
openaire +2 more sources
PMM2-congenital disorder of glycosylation (PMM2-CDG) is caused by genetic defects in PMM2, the gene encoding phosphomannomutase 2. Effective therapies for this disorder remain elusive. Recent studies emphasize cysteine's vulnerability to oxidative modifications that can instigate disease by facilitating inter-protein disulfide bonding, reducing protein
Jingmiao, Sun +8 more
openaire +2 more sources
Retinal characteristics of the congenital disorder of glycosylation PMM2‐CDG
Journal of Inherited Metabolic Disease, 2013AbstractThe congenital disorder of glycosylation, PMM2‐CDG, is associated with progressive photoreceptor degeneration, which causes a pigmentary retinopathy. We identified a sibling pair, mildly affected with PMM2‐CDG, who showed preserved photoreceptor function, but profound deficits of the ‘on‐pathway’ in the retina. This localises the site of early,
Dorothy A, Thompson +5 more
openaire +2 more sources

